Patent estate

Tarsus Pharmaceuticals — Patent Portfolio

1 drug with active patents · 9 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 9/9 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Tarsus Pharmaceuticals' portfolio is moderately strong, with a significant cliff year in 2030 and no revenue at risk in the next 5 years.

Portfolio overview Tarsus Pharmaceuticals has a total of 1 drug with patents, out of 1 total drugs in their portfolio. Their portfolio consists of 9 active US patents, with no expired US patents. The average vulnerability score of their patents is 59, indicating a moderate level of vulnerability. The company has 1 ironclad patent and 5 vulnerable patents.

Cliff calendar In 2030, 1 drug will lose exclusivity, including Xdemvy. This marks a significant cliff year for the company.

Most exposed drugs The top drug facing near-term loss of exclusivity is Xdemvy, with an earliest active patent expiry date of January 17, 2030, and an average vulnerability score of 59. Unfortunately, we do not have information on the annual revenue of Xdemvy.

Biologic exclusivity Tarsus Pharmaceuticals does not have any biologics in their portfolio.

Strategic implications With no revenue at risk in the next 5 years, the company has an opportunity to focus on lifecycle management strategies. Consideration should be given to subQ switches, label extensions, and combination filings to maximize revenue potential.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2030 1 2038

Patent estate by drug

Xdemvy (LOTILANER)

Cliff 2030 · 4y
Composition of Matter 1 Formulation 3 Method of Use 5
  • US12171750 Vuln 75 2038-12-14
    This patent protects methods for treating or preventing ophthalmic and dermatologic conditions, including blepharitis, using an isoxazoline parasiticide or other active ingredient.
  • US11197847 Vuln 70 2038-12-14
    This patent protects methods for treating or preventing ophthalmic and dermatologic conditions, including blepharitis, using an isoxazoline parasiticide or other active ingredient.
  • US11690827 Vuln 70 2038-12-14
    This patent protects methods for treating or preventing ophthalmic and dermatologic conditions, including ocular surface conditions, using a specific type of medication formulation…
See all 9 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 5 patents
  • Formulation 3 patents
  • Composition of Matter 1 patent

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Tarsus Pharmaceuticals's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export